Target
Thymidylate synthase (TYMS)
43 abstracts
Abstract
Nationwide real-world practice pattern and clinical data of palbociclib in patients with HR(+), HER2(-) metastatic breast cancer (KCSG BR21-15).Org: Division of Medical Oncology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea, Department of Internal Medicine, Seoul National University Hospital, Seoul, Seoul, South Korea, Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea, Division of Medical Oncology, Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea,
Abstract
NRG Oncology/RTOG 0848: Results after adjuvant chemotherapy +/- chemoradiation for patients with resected periampullary pancreatic adenocarcinoma (PA).Org: Rush University Medical Center, NRG Oncology SDMC/ACR, Mount Sinai Medical Center, University of Maryland, Baltimore, MD, Brown University School of Medicine-Rhode Island Hospital,
Abstract
Circulating tumor DNA detection after neoadjuvant chemotherapy and prediction of distant relapse free survival, local recurrence, and distant recurrence in triple-negative breast cancer in the TRICIA study.Org: Lady Davis Institute of the Jewish General Hospital, Jewish General Hospital Stroll Cancer Prevention Centre, Montreal, QC, Canada, Canada, Jewish General Hospital-Sir Mortimer B. Davis Jewish General Hospital,
Abstract
Modulation of lipid metabolism associated with response to metronomic capecitabine plus camrelizumab in patients with refractory gastrointestinal cancer: A prospective, single-center, exploratory trial.Org: Department of Oncology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, Key Laboratory of Systems Health Science of Zhejiang Province, School of Life Science, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou, China, Department of Oncology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China, Shanghai Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, Department of Radiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China,
Abstract
A modular, open-label, phase I/IIa study to evaluate the safety, tolerability, pharmacokinetics (PKs) and anti-tumour activity of a first-in-class (FIC) specific dUTPase inhibitor CV6-168 combined with anti-cancer treatments in patients (pts) with advanced malignancies.Org: Newcastle University and Northern Centre for Cancer Care, University of Sheffield, CV6 Therapeutics (NI) Ltd, Newcastle University and Northern Centre for Cancer Care, Newcastle Hospitals NHS Trust,
Abstract
Primary prophylaxis with pegylated-granulocyte colony-stimulating factor for patients with unresectable pancreatic cancer treated with modified-FOLFIRINOX: A randomized phase II trial.Org: Haeundae Paik Hospital,
Abstract
First-line serplulimab plus HLX04 and XELOX versus placebo plus bevacizumab and XELOX in metastatic colorectal cancer: A phase 2/3 study.Org: Shanghai Henlius Biotech Inc.,
Abstract
Interim results of the randomized phase 2 cohort of study FW-2020-01 assessing the efficacy, safety and pharmacodynamics of CM24 in combination with nivolumab and chemotherapy in advanced/metastatic pancreatic cancer.Org: Gastrointestinal and Endocrine Tumor Unit Vall d'Hebron University Hospital and Vall d'Hebrón Institute of Oncology (VHIO), Barcelona, Spain, Yale University School of Medicine, New Haven, CT, Sheba Medical Center, Ramat Gan, and Tel Aviv University, Tel Aviv, Israel, Rambam Medical Center, Haifa, Israel, HonorHealth Research Institute, Scottsdale, AZ,
Abstract
Comparative analysis of first-line therapy with fruquintinib plus chemotherapy versus standard therapy in advanced metastatic colorectal cancer (mCRC): A prospective cohort study compared with propensity score matching (PSM) cohort.Org: Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan, China, Huangshi Central Hospital of Hubei Province, Huangshi, China, Department of Oncology, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China, Hubei Cancer Hosp, Wuhan, China, Department of Abdominal Oncology, Hubei Cancer Hospital, Wuhan, China,
Abstract
Overall survival results from the phase 2 NIVOFGFR2 study of first-line nivolumab plus CAPOX in patients with FGFR2-positive, PD-L1-positive metastatic gastric cancer.Org: Bureau for Cancer Research - BUCARE, Todua Clinic, Tashkent State Dental Institute,
Abstract
Neoadjuvant chemotherapy with FOLFOXIRI plus lateral lymph nodes dissection for the treatment of resectable rectal cancer with lateral lymph node metastasis: A single-arm, investigator-initiated, phase II trial.Org: State Key Laboratory of Molecular Oncology and Department of Radiation Oncology, Comprehensive Third Ward, Cancer Institute & Hospital,
Abstract
A phase II study of cadonilimab plus mFOLFIRINOX as induction therapy for locally advanced pancreatic adenocarcinoma (LAPC).Org: Nanjing, China, Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital,
Abstract
Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): 45-month (mo) follow-up from CheckMate 648.Org: Affiliated Hospital Cancer Center, Academy of Military Medical Sciences, Institute of Cancer of São Paulo, University of São Paulo, Ono Pharmaceutical Company Ltd.,
Abstract
Neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery followed by adjuvant docetaxel and S-1 for patients with large type 3 or type 4 gastric cancer: Short-term outcomes of the phase II OGSG1902 trial.Org: Rinku General Medical Center, Tokyo Medical and Dental University Hospital, Osaka National Hospital, Osaka Prefectural General Medical Center, Izumi City General Hospital,
Abstract
Treatment (Tx) patterns, efficacy and safety of eribulin for advanced and heavily pretreated breast cancer (ABC): Updated results from a single-center, real-world study.Org: Jiaotong University,
Abstract
Pembrolizumab (pembro) + chemotherapy (chemo) for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Updated results from the KEYNOTE-859 study.Org: University Hospital Marqués de Valdecilla, IDIVAL, Santander, Spain, Hospital Nossa Senhora da Conceição, Porto Alegre, Brazil, Pontifica Catholic University of Chile, Santiago, Chile, IMAT-Oncomedica, Monteria, Colombia, Trinity St. James Cancer Institute, Dublin, Ireland,
Abstract
Beamion LUNG-2: A phase III randomized controlled trial of zongertinib (BI 1810631) versus standard of care (SoC) in patients with locally advanced/metastatic non-squamous non-small cell lung cancer (NSCLC) harboring HER2 tyrosine kinase domain (TKD) mutations.Org: Boehringer Ingelheim (Canada) Ltd,
Abstract
Neoadjuvant toripalimab plus chemotherapy followed by concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma (GASTO 1071).Org: Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center Gansu Hospital, Department of Traditional Chinese Medicine/ Integrative Oncology,
Abstract
A phase 2 study of BOLD-100 in combination with FOLFOX chemotherapy in patients with pretreated advanced biliary tract cancer: Efficacy and safety analysis (BOLD-100-001).Org: Translational Research in Oncology, Canada,
Abstract
Prediction of therapeutic response and cancer outcomes in solid tumours via in silico clinical trials.Org: Concr LTD, Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow,
Abstract
Effectiveness and safety analysis of serplulimab-based regimens in patients with HER2-negative advanced gastric cancer from a real-world retrospective study.Org: the Fourth Affiliated Hospital of Soochow University,
Abstract
Neoadjuvant chemotherapy with albumin-bound paclitaxel plus cisplatin and capecitabine for locally advanced esophageal squamous cell carcinoma: A prospective phase II trial.Org: National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, Chinese Academy of Medical Sciences and Peking Union Medical College, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Science,Peking Union Medical College,
Abstract
Hepatic artery infusion chemotherapy combined with immune checkpoint inhibitors and tyrosine kinase inhibitors for advanced hepatocellular carcinoma with portal vein tumor thrombus: A single center retrospective study.Org: Department II of Interventional Radiology,
Abstract
Hepatic artery infusion of FOLFOX chemotherapy and camrelizumab combined with sorafenib for advanced stage hepatocellular carcinoma (Double-IA-001): A phase II trial.Org: Sun Yat-sen University Cancer Center Gansu Hospital, Guangzhou JOYO Pharma, China National Biotec Group,
Abstract
Adjuvant chemotherapy with mFOLFOXIRI versus mFOLFOX6 in MRD-positive stage II-III colorectal cancer.Org: Department of Medical Oncology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, The Sixth Affiliated Hospital, SYSU, Guangzhou, China, The Sixth Affiliated hospital, Sun Yat-sen University, Guangzhou, China, Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, Third Affiliated Hospital of Kunming Medical University, Kunming, China, Department of Colorectal Surgery, The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, China,
Abstract
Modifying the gastric tumor microenvironment with tadalafil: A transcriptomic analysis of immune signatures from underserved patients of southern Arizona.Org: The University of Arizona Cancer Center, University of Arizona Cancer Center, University of Arizona College of Medicine, Phoenix, AZ,
Abstract
An open-label, placebo-controlled, randomized phase II trial of camrelizumab combined with or without apatinib or capecitabine in the treatment of previously treated advanced pancreatic cancer.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Fudan University Shanghai Cancer Center, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine,
Abstract
A real-world experience of hepatic arterial infusion chemotherapy combined with tislelizumab and lenvatinib for unresectable hepatocellular carcinoma with type IV portal vein tumor thrombus.Org: Department II of Interventional Radiology,
Abstract
A phase II trial of pembrolizumab plus platinum-based chemotherapy as first-line systemic therapy in advanced penile cancer: HERCULES (LACOG 0218) trial.Org: Hospital Universitário de Brasília, Fundação Amaral Carvalho, Instituto Nacional do Câncer (INCA), Oncológica do Brasil, BP - Beneficência Portuguesa de São Paulo,
Abstract
PIPAC in patients with peritoneal metastases from gastrointestinal tract (PIPOX): An open label, non-comparative phase 1/2 dose escalation and expansion trial.Org: Institut Cancérologique de l'Ouest, EMR 3738 Université Claude Bernard Lyon 1, Hopital d'instruction des armées de Begin, Lariboisiere Hospital - APHP, Insitut de Cancerologie de L'ouest,
Abstract
Neoadjuvant camrelizumab combined with chemotherapy for resectable stage IIIA-IIIb non-small cell lung cancer: Single arm phase II study.Org: Shandong Academy of Medical Sciences,
Abstract
High-dose furmonertinib in combination with intraventricular chemotherapy for EGFR exon 20 insertion mutated lung adenocarcinoma with leptomeningeal metastasis.Org: Nanjing Chest Hospital, Nanjing Gaochun People's Hospital,
Abstract
Safety and efficacy of PEG-rhG-CSF as primary prophylaxis against neutropenia induced by combination chemotherapy regimens involving oral chemotherapy agents in gastrointestinal cancer patients: A prospective, exploratory, non-randomized controlled study.Org: Graduate School of Shanxi Medical University, First Hospital of Shanxi Medical University, Luzhou District People's Hospital, Changzhi City,
Abstract
Cancer of unknown primary with gastrointestinal profiles: A distinct CUP subset.Org: Baylor College of Medicine, University of Texas MD Anderson Cancer Center, MD Anderson Cancer Center, MD Anderson Cancer Center Hematology/Oncology, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,
Abstract
Atezolizumab plus tiragolumab in combination with chemoradiotherapy in localized squamous cell carcinoma of the anal canal: TIRANUS (GEMCAD-2103) trial.Org: Vall d’Hebron University Hospital/VHIO, Vall d’Hebron Institute of Oncology (VHIO), Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy, Hospital Universitario Son Espases, Hospital Arnau de Vilanova; GEICAM Spanish Breast Cancer Group,
Abstract
MyTACTIC: Afficacy and safety of atezolizumab (atezo) + chemotherapy (chemo) in patients (pts) with advanced unresectable/metastatic solid tumors with high tumor mutational burden (TMB-H) or high microsatellite instability (MSI-H)/deficient mismatch repair (dMMR).Org: Sarah Cannon Research Institute/Tennessee Oncology, Tennessee Oncology, PLLC, Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL, OneOncology, Inc., New York Cancer and Blood Specialists,
Abstract
A single-arm phase 2 study of peri-operative immune checkpoint inhibition and cryoablation in women with hormone receptor-negative, HER2-negative, early-stage/resectable breast cancer.Org: University of Texas Southwestern Medical Center, Memorial Sloan Kettering Cancer Center, CLION-CAM Group, Cedars-Sinai Medical Center, Cedars-Sinai Cancer,
Abstract
ADJUBIL: A phase II study of immunotherapy with durvalumab and tremelimumab in combination with capecitabine or without capecitabine in adjuvant situation for biliary tract cancer.Org: Krankenhaus Nordwest, University Cancer Center Frankfurt and Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest, Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest, Uniklinik Göttingen, Universitätsklinikum Ulm,
Abstract
Adverse events in real-world patients covered by Medicare with metastatic pancreatic ductal adenocarcinoma who received first-line FOLFIRINOX.Org: Milliman, Inc., Ipsen Biopharmaceuticals, Inc., George Washington University Hospital,
Abstract
Making sense of the dollars: Evaluation of financial toxicity in patients of breast medicine receiving oral chemotherapy at Roswell Park.Org: Roswell Park Comprehensive Cancer Center, The D'Youville University School of Pharmacy,
Abstract
Phase II trial of safety and efficacy of tislelizumab plus chemotherapy in stage II-IV non small cell lung cancer (LungMark).Org: Department of Thoracic Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, China, Laboratory of Drug Metabolism and Pharmacokinetics, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, China, Guangzhou, China, Department of Thoracic Surgery, Jiangmen Central Hospital, Jiangmen, China, Department of Thoracic Surgery, Cancer Center of Guangzhou Medical University, Guangzhou, China,
Abstract
Establishing functional models of peritoneal carcinomatosis using MicroOrganoSphere (MOS) technology.Org: University of Texas MD Anderson Cancer Center, Xilis Inc, Xilis Inc., University of Texas at MD Anderson Cancer Center, Xilis, Inc.,
Abstract
Adjuvant capecitabine in advanced nasopharyngeal carcinoma following concurrent chemoradiotherapy: A meta-analysis and systematic review.Org: Lung Center of the Philippines, University of the Philippines- Philippine General Hospital, Makati Medical Center, National Cancer Centre Singapore,